Today: 9 June 2026
Tesla’s Stock Skyrockets on AI Hype – Latest Price Jump, Earnings Shocks & Bold 2025 Forecasts
7 November 2025
3 mins read

Tesla (TSLA) premarket today — Nov 7, 2025: Musk’s $1T pay wins approval; China FSD timeline, ‘terafab’ chip plan, and what to watch before the bell

Published: November 7, 2025


Key takeaways

  • TSLA is indicating higher before the open. As of 4:05 a.m. ET, Tesla traded around $453.81 in premarket, about +1.8% vs. Thursday’s close of $445.91. Shares also firmed to $452.93 in after-hours on Thursday. Premarket indications can change quickly.
  • Shareholders approved Elon Musk’s record pay package. A new $1 trillion performance award passed with over 75% support at Thursday’s annual meeting in Austin. The plan is tied to aggressive targets (including valuation, robotaxis and humanoid robots).
  • China FSD timing: Musk said he expects full approval of Full Self‑Driving (FSD) in China early 2026 (following partial approval this year).
  • AI chips & capacity: Musk floated building a “gigantic chip fab” for Tesla’s next‑gen AI chips and said it’s “worth having discussions” with Intel on manufacturing. Reuters
  • Macro risk at 8:30 a.m. ET: The U.S. Employment Situation (October) lands 60 minutes before the opening bell—often a major factor for high‑beta names like TSLA. CPI for October is due next Thursday (Nov 13).

Premarket snapshot: price, context, tone

Tesla closed Thursday at $445.91 (-3.5%) after a choppy session, then firmed to $452.93 after hours and is pointing higher before today’s open around $453.81. The modest bid coincides with shareholders’ approval of Musk’s new compensation plan and optimism around Tesla’s AI/robotics roadmap. (Prices are delayed; premarket quotes are indicative.)


The news moving TSLA this morning

1) Shareholders approve Musk’s $1T package

Investors gave Elon Musk a fresh, performance‑based compensation plan that could be worth up to $1 trillion over the next decade if Tesla meets sweeping milestones. Multiple outlets report more than 75% of votes were cast in favor. The plan sharpens Tesla’s pivot from a pure EV story toward AI, robotaxis (“Cybercab”), humanoid robots (Optimus) and energy/compute at massive scale. Reuters+1

Why it matters:

  • The vote reduces near‑term uncertainty over Musk’s commitment and influence at Tesla.
  • Governance debate isn’t going away, but bulls see the approval as clearing a path for the AI/robotics valuation narrative to stay front‑and‑center.

2) China FSD: full approval “early 2026”

Musk told shareholders he expects full regulatory approval for FSD in China in February–March 2026, after partial approval earlier this year. China remains Tesla’s most strategically vital overseas market; broader FSD availability there would open new software revenue and data advantages.

3) Musk floats a Tesla “terafab” for AI chips; open to Intel discussions

At the meeting, Musk said Tesla likely needs a “gigantic chip fab” to build its AI5 (and beyond) inference/training chips at volume, adding it’s “worth having discussions” with Intel on manufacturing. He also referenced TSMC and Samsung as ongoing partners. A home‑grown chip ramp could ease dependence on third‑party supply and sharpen Tesla’s AI margins over time—execution and capex will be the swing factors. Reuters

4) Product roadmap notes from the meeting

Coverage of the event highlighted timelines Musk reiterated or teased: Cybercab (robotaxi) production targeted for April 2026, the next‑gen Roadster unveiling in April 2026, and plans to scale Optimus. Timelines remain ambitious and conditional on regulatory and manufacturing readiness.


Today’s market setup: what matters before the bell

  • Jobs report (8:30 a.m. ET): The October Employment Situation can sway yields and high‑beta tech. A “hot” print tends to lift rates and weigh on long‑duration growth stocks; a “cool” print can do the opposite. Keep an eye on the two‑year and 10‑year Treasury moves into the open. CPI (Oct) follows on Thursday, Nov 13—another macro catalyst for risk appetite. Bureau of Labor Statistics+1
  • Positioning into weekly expiry:Nov‑7 weekly TSLA options show heavy interest in near‑the‑money calls (e.g., $450–$455 strikes appearing among the morning’s most active contracts), underscoring a trader focus on a post‑vote pop and macro‑headline volatility. (Options activity is dynamic; check live screens.)

How to frame TSLA right now

Bull case this morning: Governance overhang eases; China FSD path gets a clearer timeline; AI chip capacity plans reinforce the “physical AI” thesis (robotaxis, humanoids, energy + software). If the jobs report is benign and yields stay contained, the backdrop could support a bid in high‑beta mega caps—TSLA included. Reuters+1

Bear case / Risks: Execution remains enormous—regulatory approvals (especially for Cybercab/FSD in multiple jurisdictions), capex intensity for chips and robotics, and a still‑competitive global EV market. The governance debate isn’t settled for skeptics; some large institutions remain critical of concentration of power and dilution concerns. Macro (jobs/CPI) can quickly overwhelm single‑name narratives intraday.


By the numbers (as you head into the open)

  • Thursday close:$445.91
  • After‑hours (Thu):$452.93 (~+1.6% vs. close)
  • Premarket (Fri ~4:05 a.m. ET):$453.81 (~+1.8% vs. close)
    (All quotes delayed; premarket levels move rapidly.)

Bottom line

Going into the Nov 7 open, TSLA is trading the post‑vote narrative: Musk stays, AI/robotics push intensifies, China FSD timeline firmed up, and chip capacity ambitions escalate. Near‑term price action likely pivots on the 8:30 a.m. ET jobs report and whether broader risk sentiment cooperates. For now, the tape points modestly higher as bulls try to lean into the newly re‑centered AI + autonomy story.


Disclosure: This article is for news and informational purposes only and does not constitute investment advice. Always do your own research and consider your risk tolerance before trading or investing.

Stock Market Today

  • Docebo (TSX:DCBO) Valuation Story Shifts Amid Revised Earnings Guidance
    June 9, 2026, 10:40 AM EDT. Docebo's fair value remains at CA$35.97 despite updated financial models, reflecting a recalibration of valuation assumptions. Analysts highlight contrasting bullish views, citing a clear growth story backed by recent revenue guidance raising full-year 2026 estimates to US$271-275 million, against bearish concerns over limited analyst coverage and potential risks. The e-learning software provider forecast revenue of approximately US$65.4-65.6 million for Q1 2026, and US$66.7-66.9 million for Q2. At its Inspire 2026 event, Docebo unveiled a next-generation learning platform and key product updates, signaling strategic progress. Investors should monitor shifting assumptions and sector context amid evolving market narratives.

Latest articles

Autozi Shares Jump 400%, Filing Flags Risks for AZI

Autozi Shares Jump 400%, Filing Flags Risks for AZI

9 June 2026
Autozi Internet Technology shares soared over 400% to $5.69 in early Nasdaq trading after a 10-for-1 share consolidation slashed its share count to about 4.49 million, but the surge contrasts with a 63.1% revenue drop, 82.5% plunge in gross profit, and widened net loss, with the company warning of “substantial doubt” about its ability to continue as a going concern.
Redwire Shares Slip After $500 Million Stock Offering Filed

Redwire Shares Slip After $500 Million Stock Offering Filed

9 June 2026
Redwire Corp shares plunged 6.5% to $17.37 after launching a $500 million at-the-market stock program, raising dilution risks for investors as the company seeks flexible funding despite recent record backlog and strong revenue growth; the drop contrasted with gains at other space stocks, highlighting investor concern over potential share issuance.
Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

9 June 2026
Nuvalent shares soared 38.9% to $122.93, just below GSK’s $124-a-share cash offer after the $10.6 billion buyout was announced, as investors bet on the deal closing with Nuvalent’s two lead lung-cancer drugs already under FDA review and a 40% premium to the last closing price driving the morning’s merger-arb trade.
Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
Interstellar Comet 3I/ATLAS: A Visitor from Beyond the Solar System
Previous Story

Comet 3I/ATLAS today (6 Nov 2025): China’s Mars orbiter snaps new photos as the interstellar visitor turns bluer and shows puzzling acceleration

Bubble or Boom? Magnificent Seven Stocks Face Critical Earnings Showdown
Next Story

Alphabet (GOOGL) Stock Today, Nov 7, 2025: Shares Slip ~2.6% as YouTube TV–Disney Blackout Persists; DOJ Clears $32B Wiz Deal

Go toTop